Pazopanib shows promise as Ewing’s sarcoma treatment
Researchers report success in using pazopanib to treat young patients diagnosed with deadly Ewing’s sarcoma. They published their findings on Oct. 23, 2025 in Frontiers in Oncology As… read more.
Researchers report success in using pazopanib to treat young patients diagnosed with deadly Ewing’s sarcoma. They published their findings on Oct. 23, 2025 in Frontiers in Oncology As… read more.
Soft tissue injuries of the gastrointestinal tract, like ulcers or hemorrhages, can currently be treated only with some form of surgery, which is invasive and may not result… read more.
When older adults living in nursing homes are prescribed the pain medicine tramadol alongside certain antidepressants, their risk of seizures may go up, according to a study published… read more.
The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published… read more.
Metabolic dysfunction-associated steatotic liver disease is the most common liver disease in the world, affecting about one third of the adult population. This disorder is characterized by the… read more.
A widely available and affordable drug has been shown to be effective in treating seriously ill COVID-19 patients, according to a new international study led by researchers at… read more.
Eisai Co., Ltd. announced that the in-house discovered and developed orexin receptor antagonist Dayvigo (brand name in China: “达卫可®“ generic name: lemborexant) has launched in China for the… read more.
The European Medicines Agency (EMA) has recommended 14 new medicines for approval at its September meeting. The key Committee on Human Medicinal Products (CHMP) reviews safety and efficacy… read more.
NICE(UK): Guselkumab can be used as an option for previously treated moderately to severely active Crohn’s disease in adults, when: i) conventional or biological treatment: a) has not… read more.
Researchers report that patients with psoriasis treated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) have achieved a 78% reduced risk of death and a 44% reduced risk of major… read more.
Alvotech and Advanz Pharma announced that the European Commission has approved Mynzepli as a biosimilar to Eylea (aflibercept), in a pre-filled syringe and vial. The centralized marketing authorization… read more.
Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF),… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.